Eva Ståhl Wernersson has played a crucial role at ChemoTech, demonstrating considerable dedication to ensuring the company's compliance with regulations and quality assurance standards. One of her notable achievements includes leading the effort to obtain CE marking for the IQwave 3.0 CE system, our flagship product.

"I am grateful for the opportunity to have led our regulatory and quality initiatives at ChemoTech. It has been a privilege to work alongside such talented individuals dedicated to upholding the highest standards. I am confident that the foundation we've laid will continue to drive success for the company in the future." - says Eva Ståhl Wernersson, QM & RA Director

"We would like to express our sincere thanks to Eva for her dedicated service and many achievements during her time with us," said Mohan Frick, CEO. "Through her leadership, we have strengthened our commitment to regulatory excellence and positioned ChemoTech as a respectable Company within our industry. We all wish Eva the best of luck in the future."

The recruitment process of a new quality and regulatory manager has already begun. Eva's last day at the Company is set to the 30th of July 2024.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.